AZN Fair Value Estimate
$228.3723.6% undervalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Astrazeneca plc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - General
AstraZeneca (LSE/STO/Nasdaq: AZN ) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
Did you know?
Pays a 1.73% dividend yield.
Current Price
$184.74
-1.40%GoodMoat Value
$228.37
23.6% undervaluedProfile
Valuation (TTM)
Market Cap$286.51B
P/E27.58
EV—
P/B5.89
Shares Out1.55B
P/Sales4.74
Revenue$60.44B
EV/EBITDA15.28
Astrazeneca plc (AZN) Valuation
AZN Valuation Metrics
FCF$11.78B
FCF Growth Rate34.08%
EPS Growth (CAGR)40.40%
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →AZN Valuation & Fair Value Analysis
Astrazeneca plc (AZN) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Astrazeneca plc is $228.37. The current stock price is $184.74, suggesting the stock is 23.6% undervalued.
The price-to-earnings (P/E) ratio is 27.58. Price-to-book ratio is 5.89. Price-to-sales ratio is 4.74. Enterprise value to EBITDA is 15.28. PEG ratio is 4.71.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Astrazeneca plc's intrinsic value.